Tosymra (Sumatriptan) Patent Expiration, LOE Window & CMS Spending
Tosymra (Sumatriptan) by Tonix Medicines: FDA Orange Book LOE 2031-07-19, 4 AB generics, $945K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Tonix Medicines |
| FDA Application & Pathway | N210884 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-07-19 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $945K |
| 2024 Medicare Part D Spend | $382K |
| 2024 Medicaid Spend | $563K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |